This Article Full Text Full Text (PDF) All Versions of this Article: 117/7/923    most recent CIRCULATIONAHA.107.730416v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ortolani, P. Articles by Maresta, A. Search for Related Content PubMed PubMed Citation Articles by Ortolani, P. Articles by Maresta, A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Angioplasty Related Collections Type 1 diabetes Type 2 diabetes Catheter-based coronary interventions: stents Restenosis Related Article

(Circulation. 2008;117:923-930.)
© 2008 American Heart Association, Inc.

Interventional Cardiology

Two-Year Clinical Outcomes With Drug-Eluting Stents for Diabetic Patients With De Novo Coronary Lesions

Results From a Real-World Multicenter Registry

Paolo Ortolani, MD; Marco Balducelli, MD; Paolo Marzaroli, MSc; Giancarlo Piovaccari, MD; Alberto Menozzi, MD; Vincenzo Guiducci, MD; Pietro Sangiorgio, MD; Fabio Tarantino, MD; Giuseppe Geraci, MD; Fausto Castriota, MD; Stefano Tondi, MD; Francesco Saia, MD, PhD; Robin M.T. Cooke, MA; Paolo Guastaroba, MSc; Roberto Grilli, MD; Antonio Marzocchi, MD; Aleardo Maresta, MD

From the Istituto di Cardiologia, Università di Bologna, Policlinico S. Orsola-Malpighi (P.O., F.S., R.M.T.C., A. Marzocchi); Unità Operativa di Cardiologia–Centro Interventistico, Ospedale S. Maria delle Croci, Ravenna (M.B., A. Maresta); Unità Operativa di Cardiologia, Ospedale degli Infermi, Rimini (G.P.); Divisione di Cardiologia, Ospedale Maggiore, Parma (A. Menozzi); Unità Operativa di Cardiologia Interventistica, Ospedale S. Maria Nuova, Reggio Emilia (V.G.); Divisione di Cardiologia, Ospedale Maggiore, Bologna (P.S.); Laboratorio di Emodinamica, Ospedale Morgagni, Forlì (F.T.); Laboratorio di Emodinamica, Policlinico di Modena, Modena (G.G.); Casa di Cura Villa Maria Cecilia Hospital, Cotignola (F.C.); Nuovo Ospedale S. Agostino, Modena (S.T.); and Agenzia Sanitaria Regionale Regione Emilia-Romagna Bologna, Bologna (P.H., P.G., R.G.), Italy.

Correspondence to Paolo Ortolani, MD, Institute of Cardiology, University of Bologna, Azienda Ospedaliera S. Orsola-Malpighi, Via Massarenti 9, 40138, Bologna, Italy. E-mail paortol{at}tin.it

Received July 26, 2007; accepted December 14, 2007.

Background— The long-term effectiveness of drug-eluting stents (DES) in unselected diabetics in routine practice is currently unclear.

Methods and Results— To evaluate the long-term effectiveness of bare metal stents and DES in a real-world setting of diabetic patients, we analyzed 2-year follow-up data from all diabetic patients with de novo lesions enrolled in a prospective Web-based multicenter registry (Registro Regionale Angioplastiche dell’Emilia-Romagna; study period, 2002 to 2004) comprising all 13 hospitals performing percutaneous coronary interventions in the Emilia-Romagna region of Italy. Among the 1648 eligible patients treated with either bare metal stents alone (n=1089) or DES alone (n=559), 27% were insulin dependent and 83% had multivessel coronary disease. At 2 years, use of DES was associated with lower crude incidence of major adverse cardiac advents (all-cause mortality, nonfatal myocardial infarction, and target vessel revascularization) compared with bare metal stents (22.5% versus 28.1%; P=0.01). After propensity score adjustment, only target vessel revascularization appeared significantly lower in the DES group (11.6% versus 15.0%; hazard ratio, 0.66; 95% confidence interval, 0.46 to 0.96; P=0.041). Two-year angiographic stent thrombosis occurred in 1.5% DES patients and 0.7% of the bare-metal-stents patients (P=0.18). At Cox regression analysis, predictors of 2-year major adverse cardiac advents were left ventricular ejection fraction <35%, Charlson comorbidity index, insulin-dependent diabetes, and total lesion length.

Conclusions— In this large, real-world, diabetic population, the use of DES was associated with a moderate reduction in the 2-year risk of target vessel revascularization, a benefit that was limited to non–insulin-dependent diabetic patients. Larger long-term studies are needed to clarify the long-term effectiveness and safety of such devices in diabetic patients.

---

 

CLINICAL PERSPECTIVE

Related Article:

Clinical Summaries
Circulation 2008 117: 857-859. [Full Text]